Jerusalem, March 31, 2026 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®  today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference . This marks the first time that clinical result

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Showcasing Immune-Preservation and High Disease Control

Alpha Tau announced the submission of the first module of its pre-market approval (PMA) application FDA